Abstracts tagged "COVID-19"

Abstract Number: 1341 • ACR Convergence 2022
Clinical Outcomes of COVID-19 Vaccination and Booster in Patients with Autoimmune Inflammatory Rheumatic Diseases
Silera Holguin Balbuena, Anna Radisic, Sarah Goodman, Shreya Gor, Beatrice Wood, Alexander Shahin, Kelara Samuel, Rahul Mhaskar and John Carter, University of South Florida, Tampa, FL
Background/Purpose: The spread of COVID-19 began in December 2019 and quickly escalated into a global pandemic resulting in millions of deaths. Many factors are associated…
Abstract Number: 1778 • ACR Convergence 2022
More Than Half of RA Patients with a Lifetime History of Mood Disorders or Anxious and Depressed During COVID-19 Pandemic
Susan Bartlett¹, orit schieir², Marie-France Valois², Diane Tin³, Glen Hazlewood⁴, Louis Bessette⁵, Gilles Boire⁶, Carol Hitchon⁷, Janet Pope⁸, Carter Thorne⁹ and Vivian Bykerk¹⁰, ¹McGill University, Montreal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³The Arthritis Program Research Group, Newmarket, ON, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ⁶Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY
Background/Purpose: Chronic stress and chronic disease are risk factors for anxiety and depression. In Canadians with RA, pandemic-related stress was exacerbated by delayed access to…
Abstract Number: 1961 • ACR Convergence 2022
COVID-19 mRNA Vaccine Induced Antibody Titers and IFN-g Responses Are Decreased in Persons with Rheumatoid Arthritis and Older Age
Holly Dudley¹, megan O'Mara², Ann Auma¹, Jenny Gong³, Yael Ross⁴, Natalie Gurevich², Larraine Gordesky⁵, Nora Singer⁶, Lenche Kostadinova⁷, Brigid Wilson⁷, David Zidar⁷, Christopher King¹, David Canaday¹, Carey Shive¹, Maya Mattar⁸ and Donald Anthony⁹, ¹Case Western Reserve University, Cleveland, OH, ²Cleveland Veteran Affairs Medical Center, Cleveland, OH, ³Case Western School of Medicine, Cleveland, OH, ⁴Case Western Reserve University at MetroHealth Medical Center, Atlanta, GA, ⁵MetroHealth Medical Center, Cleveland, OH, ⁶The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ⁷VA Medical Center, Cleveland, OH, ⁸Louis Stokes VA Medical Center, Mayfield Heights, OH, ⁹Case, VA, Metro, Chardon, OH
Background/Purpose: People with autoimmune diseases have worse outcomes if infected by SARS-CoV2. In particular, persons with rheumatoid arthritis (RA), have lower antibody responses to COVID-19…
Abstract Number: 2275 • ACR Convergence 2022
Three Dose SARS-CoV-2 Vaccination Is Associated with Reduced Risk of Breakthrough COVID-19 During Omicron Wave in Patients with Autoimmune Diseases
Caoilfhionn Connolly¹, Rachel Wallwork¹, Teresa Po-Yu Chiang¹, Mayan Teles¹, Jennifer Alejo¹, Allan Massie², Ami Shah³, Jemima Albayda¹, Lisa Christopher-Stine¹, Dorry Segev², William Werbel¹ and Julie Paik¹, ¹Johns Hopkins University, Baltimore, MD, ²NYU Langone Health, New York, NY, ³Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: While SARS-CoV-2 vaccination mitigates the risk of severe COVID-19, vaccinated patients with autoimmune diseases are more susceptible to infection despite vaccination ("breakthrough" COVID-19) and…
Abstract Number: 0082 • ACR Convergence 2022
Impact of the COVID-19 Pandemic on Healthcare Utilization Among Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients
Jean Park, W. Cliff Rutter, Will Cavers, Elisea Avalos-Reyes and Kjel Johnson, CVS Health, Lincoln, RI
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE) are considered at risk for serious COVID infections due to their…
Abstract Number: 0366 • ACR Convergence 2022
Phase II Trial of Enpatoran in Patients Hospitalized with COVID-19 Pneumonia
John McKinnon¹, Joel Santiaguel², Claudia Murta De Oliveira³, Dongzi Yu⁴, Mukhy Khursheed⁵, Flavie Moreau⁶, Lena Klopp-Schulze⁷, Jamie Shaw⁸, Sanjeev Roy⁹ and Amy Kao¹⁰, ¹Department of Medicine, Henry Ford Hospital, Detroit, MI, ²Internal Medicine, Quirino Memorial Medical Center, Quezon City, Philippines, ³Ambulatório de Pesquisa Clínica, Santa Casa de Misericórdia, Belo Horizonte, Brazil, ⁴Global Clinical Development, EMD Serono, Billerica, MA, ⁵Global Patient Safety, Merck Serono Ltd., an affiliate of Merck KGaA, Darmstadt, Germany, ⁶Global Biostatistics, EMD Serono, Billerica, MA, ⁷Translational Medicine, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁸Translational Medicine, EMD Serono, Billerica, MA, ⁹Global Clinical Development, Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany, ¹⁰EMD Serono, Billerica, MA
Background/Purpose: Enpatoran is a selective and potent dual toll-like receptor (TLR) 7/8 inhibitor in development for the treatment of cutaneous and systemic lupus erythematosus (CLE/SLE).…
Abstract Number: 0715 • ACR Convergence 2022
Safety and Immunogenicity of Mixed COVID19 Vaccine Regimens in Immune-mediated Inflammatory Diseases: An Observational Cohort
Carol Hitchon¹, Christine Mesa², Charles N Bernstein¹, Catherine Card², RuthAnn Marrie¹, Sheila O'Brien³ and John Kim², ¹University of Manitoba, Winnipeg, MB, Canada, ²Public Health Agency of Canada, Winnipeg, MB, Canada, ³Canada Blood Services, Ottawa, Canada
Background/Purpose: Data on immunogenicity and safety of COVID-19 vaccination strategies exist for the general population, however, such data are limited for immunocompromised people including those…
Abstract Number: 0780 • ACR Convergence 2022
B-cell Reconstitution Is Associated with COVID-19 Booster Vaccine Responsiveness in Previously Seronegative Rituximab Treated Rheumatic Disease Patients
Kaitlin Schultz, Deanna Jannat-Khah, DrPH, MSPH and Robert Spiera, Hospital for Special Surgery, New York, NY
Background/Purpose: Booster doses of SARS-CoV-2 vaccines continue to serve as an important strategy for containing the pandemic and may be especially important to rituximab treated…
Abstract Number: 0796 • ACR Convergence 2022
SARS-CoV-2 Vaccine in Axial Spondyloarthritis and Psoriatic Arthritis: Does Sulfasalazine Counterbalance TNFI Impaired Immunogenicity?
Carla Goncalves Schahin Saad¹, Matheus SR Silva², PERCIVAL SAMPAIO-BARROS¹, Julio Moraes³, Claudia G Schainberg², Celio Roberto goncalves¹, Andrea Shimabuco¹, Nadia Aikawa¹, Emily Figueiredo Neves Yuki¹, Sandra Gofinet Pasoto⁴, Leonard VK Kupa², Renato K Aoyama², Carlo Araujo¹, Clovis A. Silva⁵, ana Medeiros⁶ and Eloisa Silva Dutra de Oliveira Bonfa⁴, ¹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Faculdade de Medicina da Universidade de São Paulo, São Paulo, ³Faculdade de Medicina da Universidade de Sao Paulo, Jundiai, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, ⁶Faculdade de Medicina da Universidade de São Paulo, São Jose Dos Campos, Brazil
Background/Purpose: Spondyloarthritis(SpA) patients are exposed to a variety of immunosuppressors capable of reduce humoral responses to vaccination. In context of the SARS-CoV-2 pandemic, assessment of…
Abstract Number: 0994 • ACR Convergence 2022
Effect of Immunosuppression on COVID Vaccination in Systemic Lupus Erythematosus
Michelle Petri¹, Daniel Joyce², Kristin Haag², Andrea Fava³, Daniel W. Goldman¹, Diana Zhong², Shaoming Xiao⁴, Aaron M. Milstone² and Laurence S Magder⁵, ¹Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins School of Public Health, Baltimore, MD, ⁵University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD
Background/Purpose: The risk of COVID-19 infection is increased in patients with systemic lupus erythematosus (SLE), and immunosuppressive medications including corticosteroids impact the risk. Furthermore, immunosuppressive…
Abstract Number: 1345 • ACR Convergence 2022
Is Perceived Stress Associated with COVID-19 or Having a Systemic Rheumatic Disease?
Jonah Levine, Medha Barbhaiya, Vivian Bykerk, Deanna Jannat-Khah, DrPH, MSPH and Lisa Mandl, Hospital for Special Surgery, New York, NY
Background/Purpose: The SARS-CoV-2 pandemic is a worldwide mental health crisis. We evaluated perceived stress in patients seeking care for musculoskeletal conditions, and explored associations with…
Abstract Number: 1779 • ACR Convergence 2022
Psychosocial and Health Measures in Systemic Lupus Erythematosus: COVID-19 Pandemic Trends in the Georgians Organized Against Lupus Cohort
Charmayne Dunlop-Thomas¹, Gaobin Bao², Jessica Williams², S. Sam Lim¹ and Cristina Drenkard¹, ¹Emory University, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA
Background/Purpose: The COVID-19 pandemic may have a sustained impact on systemic lupus erythematosus (SLE) patients in multiple ways. In a large predominantly Black SLE cohort,…
Abstract Number: 1980 • ACR Convergence 2022
Seroconversion After a Third COVID-19 Vaccination in Rheumatoid Arthritis Patients Treated with (ultra-)low Dose Rituximab with a Previous Insufficient Humoral Response Is Associated with Rituximab Dosage
Céleste van der Togt¹, David Ten Cate¹, Janette Rahamat-Langendoen², Bart van den Bemt³, Nathan den Broeder⁴ and Alfons den Broeder⁴, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²ErasmusMC, Rotterdam, Zuid-Holland, Netherlands, ³Department of Pharmacy, Sint Maartenskliniek, Ubbergen, Netherlands, ⁴Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Around 60% of rheumatoid arthritis (RA) patients treated with ≥1000 mg rituximab (RTX) has an insufficient deemed humoral response after two COVID-19 vaccinations. Recent…
Abstract Number: PP02 • ACR Convergence 2022
Patient Mobilization for Vaccine Access and Improved Care During the COVID Pandemic
Marie-Claude Beaulieu¹, Ines Colmegna², Nathalie Amiable³, Jean Légaré⁴ and Paul Fortin⁵, ¹Universite de Sherbrooke, Sherbrooke, QC, Canada, ²The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³CHU de Québec, Quebec, QC, Canada, ⁴QC, Canada, ⁵CHU de Quebec - Universite Laval, Quebec, QC, Canada
Background/Purpose: The COVID pandemic was particularly difficult for persons like me living with rheumatoid arthritis and immunosuppressed. I had to impose myself months of isolation…
Abstract Number: 0083 • ACR Convergence 2022
COVID-19 Vaccine Uptake and Reasons for Hesitancy in a Large Rheumatology Practice Network
Amy Mudano¹, Fenglong Xie¹, Patrick Stewart², Lesley Jackson³, Maria Danila³, Kelly Gavigan⁴, William Benjamin Nowell⁵, Shilpa Venkatachalam⁶ and Jeffrey Curtis⁷, ¹Illumination Health, Hoover, AL, ²Bendcare, Boca Raton, FL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵Global Healthy Living Foundation, Nyack, NY, ⁶Global Healthy Living Foundation, New York, NY, ⁷Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Sub-optimal COVID-19 vaccine uptake by patients with autoimmune conditions is an area of concern to many rheumatologists and other providers. It is important to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].